New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 6, 2014
07:33 EDTAGIOAgios Pharmaceuticals reports Q4 EPS (40c), consensus (34c)
Reports Q4 revenue $6.74M, consensus $6.19M. Agios expects to present initial clinical data from the dose escalation portion of the ongoing Phase 1 study of AG-221 at the 2014 American Association for Cancer Research Annual Meeting in early April. Agios expects to continue enrollment in its Phase 1 study of AG-221 and initiate expansion cohorts in late 2014. Agios plans to initiate two Phase 1 clinical trials for AG-120 in early 2014 in patients whose cancers carry an IDH1 mutation. These studies will leverage the clinical trial sites of Agiosí Phase 1 study of AG-221. Agios anticipates initiating single and multiple ascending dose-escalation studies for AG-348 in healthy volunteers in mid-2014. Agios expects that its cash, cash equivalents and marketable securities will be sufficient to fund its operating expenses and capital expenditure requirements until late 2016.
News For AGIO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 21, 2014
08:40 EDTAGIOAgios Pharmaceuticals initiates Phase 1/2 clinical trial of AG-221
Subscribe for More Information
07:06 EDTAGIOFierce Biotech to hold a breakfast meeting
Subscribe for More Information
October 15, 2014
07:40 EDTAGIOAgios Pharmaceuticals initiates four expansion cohorts in AG-221 Phase 1 study
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use